Table 1.
Reference | Drug | Phase | Response (%) |
---|---|---|---|
Pappo etal. (2011) | R1507 | II | 11/115 (9.6) |
Juergens etal. (2011) | Figitumumab | I–II | 15/106 (14) |
Malempati etal. (2012) | Cixutumumab | I–II | 1/35 (2.9) |
Tap etal. (2012) | Ganitumab | II | 1/18 (5.6) |
Tolcher etal. (2009) | Ganitumab | I+tail | 2/12 (16) |
Olmos etal. (2010) | Figitumumab | I-II | 2/16 (12) |
TOTAL | 41/312 (13) |